This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.

 Previous Article  |  Next Article 

J Virol, April 1998, p. 2871-2880, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Priming with Secreted Glycoprotein G of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia after RSV Challenge

Teresa R. Johnson,1 Joyce E. Johnson,2 Sharon R. Roberts,3 Gail W. Wertz,4 Robert A. Parker,5 and Barney S. Graham1,6,*

Departments of Microbiology and Immunology,1 Pathology,2 and Medicine,6 Vanderbilt University School of Medicine, Nashville, Tennessee; Department of Botany and Microbiology, Auburn University, Auburn,3 and Department of Microbiology, University of Alabama at Birmingham, Birmingham,4 Alabama; and Department of Medicine (Biostatistics), Harvard University School of Medicine, Boston, Massachusetts5

Received 12 September 1997/Accepted 22 December 1997

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The respiratory syncytial virus (RSV) G glycoprotein promotes differentiation of type 2 CD4+ T lymphocytes and induces an eosinophilic response in lungs of RSV-infected mice. A unique feature of G is that a second initiation codon in the transmembrane region of the glycoprotein results in secretion of soluble protein from infected cells. Recombinant vaccinia viruses that express wild-type G (vvWT G), only secreted G (vvM48), or only membrane-anchored G (vvM48I) were used to define the influence of G priming on immunopathogenesis. Mice immunized with vvM48 had more severe illness following RSV challenge than did mice primed with vvWT G or vvM48I. Coadministration of purified G during priming with the construct expressing membrane-anchored G shifted immune responses following RSV challenge to a more Th2-like response. This was characterized by increased interleukin-5 in lung supernatants and an increase in G-specific immunoglobulin G1 antibodies. Eosinophils were present in the infiltrate of all mice primed with G-containing vectors but were greatest in mice primed with regimens including secreted G. These data suggest the form of G protein available for initial antigen processing and presentation is an important factor in promoting Th2-like immune responses, including the induction of lung eosinophilia. The ability of RSV to secrete G protein may therefore represent a viral strategy for immunomodulation and be a key determinant of disease pathogenesis.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Respiratory syncytial virus (RSV) is the leading cause of serious respiratory virus infections in infants and is a high priority for vaccine development. One obstacle to vaccine development is the legacy of vaccine-enhanced disease in children following natural infection (32, 34). Studies of vaccine-enhanced disease in animal models have suggested that the process is related to an altered pattern of CD4+ T-lymphocyte activation and cytokine production (5, 10, 18, 19, 35, 49, 62, 69). The G glycoprotein in particular has been implicated as an RSV antigen that promotes activation of Th2 CD4+ T lymphocytes and induces eosinophilic infiltrates in the lung following RSV challenge (2, 4, 58).

The large glycoprotein G serves as the attachment protein of RSV (40) and is one of the major glycoproteins expressed in the membrane of the virus (67, 68). The protein is expressed on the surface of infected cells and secreted into the extracellular environment (26, 27). Detailed structural studies have demonstrated that G possesses characteristics that are unusual among viral membrane proteins (31, 39, 70). These traits include secretion of the protein, extensive O-glycosylation, and a unique peptide sequence with no significant homology to other viral proteins.

RSV G protein plays a role in both induction of protective immunity and disease pathogenesis. RSV-infected children produce a well-characterized antibody response to G (23, 43, 64, 65). Passive transfer of antibodies to G (63, 66) or active vaccination with recombinant vaccinia viruses expressing RSV G (6, 45) is partially protective against live virus challenge in rodent models of RSV (60, 61, 66). Screening of a panel of monoclonal antibodies raised against RSV G demonstrated that the majority of antibodies were reactive only with the glycosylated form of the protein and did not recognize the unglycosylated protein backbone (47). When protein glycosylation was blocked or altered, production of G protein was inhibited (38). Nevertheless, a peptide fragment, hypothesized to constitute a major part of the protection domain, elicited an antibody response and reduced viral titers in immunized mice (57). While capable of inducing an antibody response, G is not a recognized target of cytotoxic T-lymphocyte-mediated immune responses in humans or mice (2, 4, 7, 8, 48, 59).

Use of recombinant vaccinia virus expressing RSV G (vacG) to prime mice generated a Th2 CD4+ T lymphocyte response, while vaccination with fusion (F) protein-expressing virus (vacF) induced a Th1 CD4+ T-cell response (2, 48). The disease profiles and lung pathology in naive mice injected with T cells from vacG- or vacF-primed mice also differed dramatically (1, 3, 46). Transfer of G-specific CD4+ T-cell clones to naive mice predisposed for more severe lung pathology and disease upon RSV challenge than did 22K- or F-specific clones (1). In vacG-primed RSV-challenged mice, bronchoalveolar lavage (BAL) revealed 14 to 25% of cells in the pulmonary infiltrate to be eosinophils, whereas <3% of cells were eosinophils in mice primed with vacF or vacN (nucleoprotein [N]-expressing vaccinia virus) (46). Attempts to promote Th1-like responses rather than Th2 responses with the adjuvant QS21 minimally decreased eosinophilia and interleukin-5 (IL-5) production induced by G priming, whereas it had a much greater effect on responses to F (25). These data suggest that the primary or secondary antigenic structure of G may influence the composition of subsequent RSV-specific immune responses, but that RSV immunization with secreted glycoproteins can itself predispose to Th2-like immune responses.

Membrane-anchored and secreted forms of G protein are produced from alternative initiation codons (52). Characterization of these two forms of RSV G demonstrate that the two proteins are structurally and antigenically similar, except for lack of the cytoplasmic tail in the secreted form of the protein. The production of two forms of G protein is a trait conserved among all known strains of RSV, suggesting that it provides an advantage for RSV survival. We have addressed the contribution of secreted G glycoprotein to the composition of subsequent RSV-specific immune responses relative to influences from the primary or secondary antigen structure of G alone. Recombinant vaccinia viruses which express the three forms of G, secreted, membrane anchored, and wild type (both secreted and membrane anchored), have been constructed (52). Using these constructs, we examined whether the route of antigen processing of the G antigen, rather than its primary or secondary antigenic structure, was the major determinant in regulating subsequent immune responses.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Virus stocks and cell lines. Recombinant vaccinia viruses were obtained that express various RSV proteins (Table 1). Viral stocks were grown and purified by density gradient centrifugation on potassium tartrate gradients, using a modification of the protocol of Hall and Martin (24). Briefly, BSC40 monolayers were infected with vaccinia virus and grown for 2 days. The infected cells and media were then harvested and sonicated, and the material was layered onto a cushion of 1.46 M sucrose-1 mM NaH2PO4 (pH 7.2). After centrifugation for 90 min at 62,000 × g, the supernatant was removed and the pelleted virions were resuspended in phosphate-buffered saline (PBS). The virus was sonicated and layered onto a continuous gradient from 0.85 to 2.13 M potassium tartrate in 0.01 M Tris-HCl (pH 8.5). The gradients were centrifuged 60 min at 62,000 × g; the opaque band of virus was removed from the gradient and sonicated. The isolated virus was washed in cold PBS and pelleted by centrifugation for 90 min at 85,000 × g. The virus pellet was resuspended in Eagle minimal essential medium (EMEM)-10% fetal calf serum (FCS), aliquoted, and stored at -70°C. All steps of vaccinia virus purification process were performed at 4°C. A stock of RSV (A2 strain) was generated in HEp-2 cells and stored at -70°C as previously described (20). All cell lines and viral stocks were determined to be free of mycoplasma contamination by PCR analysis (American Type Culture Collection, Rockville, Md.).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Products used for priming immunization

Purification of secreted RSV G protein. Monolayers of BSC40 cells were infected with vvM48 at a multiplicity of infection of 0.5. After 4 days growth, the culture supernatant was transferred to 50-ml centrifuge tubes and stored at -70°C. To separate cells and intact virions from secreted proteins, the culture supernatant was overlaid on a cushion of 1.46 M sucrose-1 mM NaH2PO4 (pH 7.2) in an SW28 ultracentrifuge tube and centrifuged 90 min at 62,000 × g in a Beckman (Palo Alto, Calif.) L8-80 ultracentrifuge. The supernatant was removed and dialyzed overnight at 4°C against 20 mM Tris-HCl-0.5 M NaCl (pH 7.4) (ConA [concanavalin A] binding buffer) and was then applied to a ConA-Sepharose lectin column (Pharmacia Biotech, Piscataway, N.J.). Unbound proteins were removed from the column by washing with binding buffer until OD280 (optical density at 280 nm) readings were less than 0.02. Bound proteins were eluted by application of a continuous gradient from 0 to 0.5 M methyl-alpha -mannopyranoside in 20 mM Tris-HCl-0.5 M NaCl (pH 7.4). Three-milliliter fractions were collected throughout the chromatographic run. Fractions were screened by capture enzyme-linked immunosorbent assay (ELISA), and G-containing fractions were pooled and concentrated in Centriprep concentrators (Amicon, Inc., Beverly, Mass.). The purified protein was stored at -70°C.

Mouse priming and challenge. Pathogen-free 8-week-old BALB/c mice were obtained from Charles Rivers Laboratories (Raleigh, N.C.) and were housed in a barrier facility. Mice were primed with 5 × 105 PFU (in 0.05 ml) of recombinant vaccinia virus by intradermal inoculation at the base of the tail and were monitored daily for lesion formation. In G reconstitution experiments, 850 ng of purified G (in 25 µl) was injected intradermally at the base of the tail on each of the days 0, 1, 2, and 3 of priming. Formalin-inactivated, alum-precipitated RSV (FI-RSV) was prepared as previously described (19) and administered intramuscularly. Six weeks after immunization (4 weeks after clearance of cutaneous lesions), the mice were anesthetized and intranasally infected with 0.1 ml containing 107 PFU of live RSV. RSV-infected mice were weighed for 12 days following challenge. Illness was graded daily by a blinded observer where clinical features of illness were scored as follows: 0, no apparent illness; 1, slightly ruffled fur; 2, ruffled fur but active; 3, ruffled fur and inactive; 4, ruffled, inactive, hunched posture, and gaunt; 5, dead.

RSV plaque assays. Four or eight days following RSV challenge, mice were sacrificed by CO2 narcosis and cervical dislocation. The lungs were removed, placed in EMEM-10% FCS, and quick-frozen in an alcohol-dry ice bath. RSV titers in the lungs were measured by standard plaque assays using 80% confluent HEp-2 monolayers. Briefly, lungs were quick-thawed and ground with a mortar and pestle. Serial 10-fold dilutions of lung supernatants were used to infect the monolayers in triplicate, and cultures were grown under 0.75% methylcellulose in EMEM-10% FCS. Cells were formalin fixed 5 days after infection and stained with hematoxylin and eosin, and plaques were counted under a dissecting microscope. Data are represented as the geometric mean log10 PFU per gram of lung tissue ± standard error of the mean (SEM) at the dilution producing more than five plaques per well.

Analysis of vaccinia virus replication in vivo. Pathogen-free 8-week-old BALB/c mice were infected with 5 × 105 PFU (in 0.05 ml) of recombinant vaccinia virus by intradermal inoculation at the base of the tail and were monitored daily for lesion formation. On days 4, 7, 12, and 17 postinfection, mice were sacrificed. Spleens and inoculation site (10 to 12 mm of tail) were removed, placed in EMEM-10% FCS, and quick-frozen. Vaccinia virus titers in each tissue sample were measured by plaque assay as described above for RSV plaque assay with modification. The modifications included use of 80% confluent BSC40 cells, a 2-day incubation, and staining with crystal violet rather than with hematoxylin and eosin.

Quantitation of IFN-gamma and IL-5 in lung tissues. Levels of gamma interferon (IFN-gamma ) and IL-5 in lung tissues of primed and challenged mice were measured using commercially available ELISA kits (Endogen, Woburn, Mass.) according to the kit protocols. Briefly, supernatants from ground lungs of primed mice 4 and 8 days following RSV challenge (used for RSV titrations above) were thawed, added to precoated wells, and incubated for 2 h. Dilutions of recombinant cytokine were included for generation of a standard curve. Peroxidase-labeled anticytokine antibody was added to detect bound cytokine, and the plates were developed by the addition of tetramethylbenzidene substrate. Concentrations of cytokine in the lung supernatants were calculated from the standard curve produced.

Histopathology of lungs from RSV-challenged mice. Mice were sacrificed 8 days after RSV challenge, and their uncut lungs were fixed in phosphate-buffered 10% formalin for histopathological examination. Thin sections of formalin-fixed, paraffin-embedded lung tissue were stained with hematoxylin and eosin. Analysis included grading the degree of cellular infiltration and edema at the level of the alveolus and determination of the types of infiltrating cells. Inflammation was assessed according to the following scale: 0, no infiltrate; 1, mixed generalized increase in interstitial mononuclear cells without widening of alveolar septa; 2, dense septal mononuclear infiltrates with septal thickening and occasional foci of intra-alveolar cells; 3, significant alveolar space consolidation (intra-alveolar edema, inflammation, or hemorrhage) in addition to interstitial inflammation. Eosinophil-specific Luna staining was used to demonstrate tissue eosinophilia.

To quantitatively assess and compare the tissue eosinophilia induced by the various priming regimens, the percentage of eosinophils was determined by counting cells in lung infiltrates. Bronchovascular bundles in which the arteries were cut in cross section (where the length and width of the diameter were <1.5× different in relative lengths) were identified in Luna-stained lung sections. Total cells and the number of eosinophils in the infiltrate around each qualifying vessel were counted. The entire infiltrate around each bronchovascular bundle was counted until the total cell count exceeded 300 cells. An average of three to five bronchovascular bundle infiltrates were counted per lung. The percentage of eosinophils were then calculated as (number of eosinophils/number of total cells) × 100.

BAL of RSV-challenged mice. Mice were sacrificed 6 days after RSV challenge. The trachea was surgically exposed, and a 19-gauge blunt-end needle was inserted into a small cut made in the trachea. Through this endotracheal tube, 0.5 ml PBS containing 5% FCS was injected into the lungs. After washing for approximately 30 s, the fluid was withdrawn and transferred to a microcentrifuge tube. Smears were made of all BAL samples and were air dried overnight. The dried smears were then stained with Diff-Quick (Fisher Scientific, Pittsburgh, Pa.), and differential counts of standard cell types were performed.

Titers and isotype profiles of G-specific antibodies. Prechallenge sera were collected from vaccinia virus-primed mice by retro-orbital bleeding the day before RSV challenge. Sera were stored at -70°C until postchallenge samples were collected. Six weeks following RSV challenge, the mice were again bled, and serum was separated and frozen. To measure G-specific antibody, Nunc Immulon II microtiter plates were coated for 1 h with purified G protein (Wyeth-Lederle, Pearl River, N.Y.), the G protein isolated from RSV subtype A virus. Serial two-fold dilutions of pre- and postchallenge sera were added to the coated wells in duplicate and incubated for 1 h. Bound immunoglobulin was detected by the addition of horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin G1 (IgG1), IgG2a, or IgG/A/M (Zymed Laboratories, San Francisco, Calif.). The plates were developed with tetramethylbenzidene. Data are represented as log2 values of the serum dilution producing 0.100 OD450 unit and greater than twice the antigen-negative well.

Production of neutralizing antibodies to RSV and vaccinia virus. Titers of neutralizing antibodies to both RSV and vaccinia virus in pre- and postchallenge sera were measured by plaque reduction neutralization assays as previously described (20).

Statistical analysis. Data from individual experiments were maintained in a Paradox database. Statistical analysis was performed by transferring data from the database into the SAS (Chapel Hill, N.C.) statistical software to perform analysis of variance using Kruskal-Wallis and Wilcoxon rank sum tests. Comparisons were made between individual experiments by using statistical modeling and trend analysis calculated by the general linear model method in the SAS package. P values less than 0.05 were considered statistically significant.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Weight loss and illness following challenge of primed mice. Mice were immunized with vaccinia virus constructs expressing F, wild-type G (vvWT G), secreted G only (vvM48), or membrane-anchored G only (vvM48I) (Table 1). Consistent with previous observations (1, 61), illness in mice vaccinated with vvWT G was more severe and weight loss was significantly greater than in vacF-immunized mice (P < 0.05 at days 4 to 12, Kruskal-Wallis test [data not shown]). Mice primed with vvM48I exhibited patterns of illness and weight loss similar to those of vvWT G-primed mice (Fig. 1; P > 0.05 at all days). However, mice immunized with vvM48 demonstrated illness and weight loss profiles significantly more severe than observed in vvM48I-primed mice (Fig. 1; P < 0.05 at all days except day 7, where P = 0.07). Thus, the presence of secreted G alone during priming, rather than membrane-anchored G, was associated with more severe disease upon subsequent RSV infection. However, the presence of membrane-anchored G can have a modulating effect on the illness profile induced by secreted G, decreasing the severity, as seen in mice immunized with vvWT G. 


View larger version (20K):
[in this window]
[in a new window]
  		FIG. 1.   Illness in vaccine-primed mice after RSV challenge. Mice were primed with either vvWT G (bullet ), vvM48I (black-lozenge ), vvM48 (black-triangle), or VSC8 (black-square) intradermally at the base of the tail and 6 weeks later challenged intranasally with live RSV. Illness was monitored for 12 days following challenge. The data represent the mean and SEM for each group from four experiments (n = 20 for all groups). P > 0.05 at days 5 to 11 when VSC8-primed mice are compared to vvM48-primed mice and when vvWT G- and vvM48I-primed mice are compared. When vvM48-primed mice are compared to vvM48I-primed mice, P < 0.05 at each day except day 7 (where P = 0.07). Illness mirrored weight loss measurements (data not shown).

RSV replication following viral challenge. When RSV titers in the lungs were measured 4 days postchallenge, the degree of viral clearance differed among the priming groups (Fig. 2). VacF priming resulted in greater reduction of RSV titers in lung than vvWT G, confirming earlier observations (45). Reduction in RSV titers in lung was similar between vvWT G- and vvM48I-primed mice. In contrast, priming with vvM48 resulted in significantly less reduction in RSV titers than did vvWT G priming (P < 0.05, Tukey's Studentized range test). Therefore, G is less immunogenic than F and secreted G appears to be less immunogenic than membrane-anchored G. 


View larger version (18K):
[in this window]
[in a new window]
  		FIG. 2.   RSV titers in lungs of vaccine-primed mice. Mice were primed and challenged as for Fig. 1. On day 4 postchallenge, viral titers were measured by standard plaque assay on HEp-2 monolayers and are represented as the log10 (PFU/gram of lung) ± SEM. Data from a representative experiment (of four) are shown (n = 6 for FI-RSV and mock-primed groups; n = 5 for all other groups; P < 0.005).

In vivo production of G. Antigen dose has been shown to influence T-cell differentiation (12, 29, 51). Thus, production of different concentrations of antigen by different virus vectors may potentially result in different profiles of immune responses following challenge. vvWT G, vvM48I, and vvM48 have been shown to produce similar levels of RSV G in vitro in tissue culture systems (52). However, due to immunoregulatory mechanisms, this may not be the case in vivo. Thus, we sought to confirm equal antigen production in vivo. Due to dissemination of vaccinia virus, a direct measure of RSV G concentrations in a given tissue was not considered to be an accurate representation of antigen production. Therefore, we measured the dissemination and titers of vvM48I and vvM48. Similar patterns of dissemination to spleen and equivalent viral titers in tail sections were observed at all time points examined (data not shown). To further evaluate replication of these two vaccinia virus constructs in vivo, neutralizing antibody titers were measured. vvM48I and vvM48 immunizations resulted in levels of neutralizing antibodies similar to those for vaccinia virus (data not shown). Production of equal amounts of G from vvM48I and vvM48 in vitro (52) suggests that in vivo levels of production of G antigen between vvM48I and vvM48 are similar.

Reconstitution with purified G during priming. To determine whether enhanced disease and reduced viral clearance produced by vvWT G and vvM48 sensitization were indeed related to the presence of secreted G during priming, immunization protocols in which purified G was coadministered early in the vaccination schedule were designed. Secreted G was purified to homogeneity from vvM48-infected cell culture supernatant by chromatography on a ConA-Sepharose affinity column (data not shown). To simulate the conditions of priming with wild-type G, purified G was administered on days 0 to 3 to vvM48I-primed mice. The immunogenicity of G alone was examined by administration of purified protein during VSC8 priming. All mice were challenged with RSV 6 weeks after immunization, and illness and weight loss were monitored. The addition of purified G during VSC8 priming established immunologic conditions in which enhanced disease occurred following RSV challenge, as evidenced by increased illness and weight loss relative to VSC8-primed mice (Fig. 3 and data not shown). Coadministration of purified G during vvM48I immunization did not result in a significant change in either illness or weight loss compared to mice primed with vvWT G or vvM48I alone.


View larger version (19K):
[in this window]
[in a new window]
  		FIG. 3.   RSV-induced illness in mice primed with RSV G-vaccinia virus constructs and RSV G reconstitution. Mice were primed intradermally at the base of the tail with the indicated constructs and challenged intranasally with live RSV 6 weeks after priming; illness was measured daily. Data from a representative experiment (of three) are shown and represented as mean ± SEM (n = 5; P < 0.05 at days 4 to 12).

Clearance of RSV was also examined in mice primed with the recombinant vaccinia constructs and purified G. While purified G in combination with VSC8 priming resulted in enhanced disease, it did not reduce RSV titers after challenge compared to mice primed with VSC8 alone (Fig. 4). Mice immunized with vvM48I had significantly lower RSV titers in lung following challenge than mice primed with vvWT G or vvM48 (Fig. 4; P < 0.05, Tukey's Studentized range test). However, in mice coimmunized with purified G and vvM48I, the RSV titers in lungs 4 days after RSV challenge were not significantly different from those in vvM48- or vvWT G-primed mice (P > 0.05). Thus, addition of purified G during vaccination alters the immunogenicity of vvM48I priming, decreasing viral clearance, suggesting secreted G actively influences the magnitude, specificity, or composition of the immune response.


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 4.   RSV titers in lungs of mice primed with RSV G-vaccinia virus constructs and RSV G reconstitution. Mice were primed and challenged as for Fig. 3. On day 4 postchallenge, viral titers were measured by standard plaque assay on HEp-2 monolayers and are represented as the log10 (PFU/gram of lung) ± SEM. Data from a representative experiment (of three) are shown (n = 5 for all groups; P < 0.0001).

G-specific antibody isotype response. Antibody titers in prechallenge sera of immunized mice were evaluated in a G capture ELISA. Detectable levels of immunoglobulin were measured in each priming group except mice primed with VSC8 (Fig. 5). Vaccination with regimens containing membrane-anchored G produced higher titers of antibody than did regimens containing only secreted G protein. Subsequent to RSV challenge, antibody titers were increased to similar levels in all groups (data not shown).


View larger version (33K):
[in this window]
[in a new window]
  		FIG. 5.   G-specific antibody titers and isotype profiles. Mice were primed and challenged as for Fig. 3. Serum samples were collected the day prior to challenge. Titers and isotypes of G-specific antibodies were measured in a capture ELISA by coating wells with purified G protein, adding dilutions of sera, and detecting bound IgG with horseradish peroxidase-conjugated anti-isotype antibodies. Prechallenge IgG1 and IgG2a were measured. Data from a representative experiment (of three) are represented as the mean ± SEM of the log2 (serum dilution) producing 0.1 OD450 unit for each group. When IgG1 and IgG2a titers were compared in each priming group, the following P values were obtained: >0.5 for VSC8, vvWT G, vvM48, and vvM48I plus G; 0.025 for VSC8 plus G; and 0.01 for vvM48I (Student's t test; n = 5 for all groups but vvWT G and vvM48, where n = 6 and 7, respectively).

In mice primed with vvM48I, IgG2a antibodies were the dominant isotype generated (n = 5, P = 0.01, Student's t test comparing IgG1 and IgG2a titers in vvM48I-primed mice). In vvWT G- and vvM48-primed mice, IgG2a were higher than IgG1 titers, but the ratio of IgG2a to IgG1 was lower. With the coadministration of secreted G during priming, a shift to IgG1-producing conditions was observed. In VSC8-primed mice which also received purified G, the major antibody response was of an IgG1 isotype (n = 5, P = 0.025 relative to IgG2a titers from the same priming group). Coadministration of secreted G during vvM48I immunization resulted in a shift from an IgG2a-dominated antibody response to a response in which IgG1 and IgG2a antibody titers were about equal. The IgG1/IgG2a ratios in vvM48I-primed mice were significantly different from the IgG1/IgG2a ratios in mice primed with vvM48I plus G (P = 0.04, Student's t test comparing IgG1/IgG2a ratios [data not shown]). Thus, addition of secreted G to the priming environment can induce a significant shift away from an IgG2a-dominated antibody response. These data suggest that the presence of secreted G during priming reinforces the tendency for G-specific responses to produce IgG1 antibodies.

Cytokine production in the lungs. The concentrations of IL-5 and IFN-gamma in the lung supernatants from mice 4 and 8 days after RSV challenge were measured by ELISA. Both IL-5 and IFN-gamma could be measured in day 4 samples and are shown in Table 2. Little IL-5 was detectable in day 8 lung supernatants, and IFN-gamma levels were greatly reduced (data not shown). Little IL-5 was measured in the lung supernatants of mice immunized with VSC8 (Table 2). Highest concentrations of IL-5 were found in mice primed with vvM48I plus G and vvM48. Statistically significant differences were found when IL-5 levels in vvWT G-primed mice were compared to those in either vvM48-primed mice or vvM48I-plus-G-primed mice (P > 0.0001, Student's t test). Similarly, compared to vvM48I-plus-G-primed mice, the IL-5 levels in vvM48I-primed mice (P = 0.01) and in vvM48-primed mice (P = 0.004) were significantly different. Mice primed with vvWT G and VSC8 plus G had intermediate IL-5 levels, and vvM48I-primed mice had the lowest levels, although the differences between the three groups were not statistically significant (P > 0.05, Student's t test). Thus, increased IL-5 levels were correlated with priming regimens that included secreted G and paralleled the titers of G-specific IgG1.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Quantitative measures of lung immunopathology in primed mice after RSV challengea

Lung pathology following RSV challenge. The alveolar inflammation induced by priming with the different forms of G protein was evaluated (Fig. 6 and 7). In mice immunized with VSC8, vvWT G, or vvM48, moderate alveolar mononuclear infiltration occurred upon RSV challenge (Fig. 6A, C, and D, respectively). In mice primed with vvWT G and vvM48, a significant eosinophil component was present in the infiltrates around arteries (Fig. 7C, D, and G). Although vvM48I priming reduced the density of infiltration (Fig. 6E), small numbers of eosinophils were still detected focally (Fig. 7E and G). When G was coadministered during VSC8 priming, the pathology resulting from challenge was more severe (Fig. 6B and G) and induced prominent eosinophilia (Fig. 7F and G), absent in mice immunized with VSC8 alone (Fig. 7A). The addition of secreted G during vvM48I priming did not significantly increase the severity of lymphocytic infiltration (Fig. 6F and G); however, this priming regimen did result in the recruitment of abundant eosinophils into the periarterial infiltrates (Fig. 7F and G). When the degree of eosinophilia was quantitatively examined (Fig. 7G), similar percentages of eosinophils were found in the lungs of mice primed with VSC8 plus G, vvWT G, and vvM48I plus G (P > 0.1, Student's t test). The addition of secreted G to vvM48I priming resulted in significantly greater percentage of eosinophils infiltrating the lung (P = 0.002, vvM48I compared to vvM48I plus G). Similar increases were found with the addition of secreted G to VSC8 priming (P < 0.0001). Thus, the presence of G-specific IgG1 titers and IL-5 content in lung correlated with the amount of tissue eosinophilia.


View larger version (205K):
[in this window]
[in a new window]
 

View larger version (17K):
[in this window]
[in a new window]
  		FIG. 6.   Lung histopathology. Mice were primed with VSC8 (A), VSC8 plus G (B), vvWT G (C), vvM48 (D), vvM48I (E), or vvM48I plus G (F) and challenged as for Fig. 3. Eight days following challenge, lung histopathology was evaluated by staining formalin-fixed lung sections with hematoxylin and eosin (original magnification, ×25). Day 8 lungs were examined and graded for severity and composition of alveolar inflammation on a semiquantitative scale (G). No statistical difference was found among any group except the VSC8-plus-G group, in which inflammation was significantly higher than in any other group (P < 0.03, Student's t test, n = 5).


View larger version (157K):
[in this window]
[in a new window]
 

View larger version (15K):
[in this window]
[in a new window]
  		FIG. 7.   Tissue eosinophilia. Mice were primed with VSC8 (A), VSC8 plus G (B), vvWT G (C), vvM48 (D), vvM48I (E), or vvM48I plus G (F) and challenged as for Fig. 3. Eight days following challenge, lung eosinophilia was evaluated by staining tissue sections with Luna's stain (original magnification, ×250). Tissue eosinophilia was quantitatively measured by counting the percentages of eosinophils in Luna-stained formalin-fixed day 8 lungs (G; n = 5). Differences between VSC8 plus G, vvWT G, and vvM48I plus G were not statistically significant. vvM48-primed mice were significantly different from all other groups (P < 0.05). P = 0.002 for vvM48I compared to vvM48I plus G; P < 0.0001 for VSC8 compared to VSC8 plus G and for vvWT G compared to vvM48I.

Cellular composition of BAL infiltrate after RSV challenge. To determine whether infiltration of cells into the air space differed from that seen in the periarterial regions and to quantitate the cellular components of the infiltrate, BAL was performed on day 6 following challenge (Table 2). The greatest number of eosinophils occurred in mice primed with VSC8 plus purified G and with vvM48, and slightly fewer eosinophils were obtained in BAL of vvWT G-primed mice, although no statistically significant difference was detected between these groups. Significantly fewer eosinophils were recruited into the bronchial airways of mice immunized with vvM48I with or without purified G (P < 0.05 relative to vvWT G or vvM48), contrasting with the increased interstitial eosinophilia observed with coadministration of secreted G during vvM48I priming (Table 2 and Fig. 7F). Therefore, groups with a high degree of BAL eosinophilia also had increased illness and weight loss. Although the degree of BAL eosinophilia generally corresponded to tissue eosinophilia, mice primed with vvM48I plus G had a higher frequency of tissue eosinophilia yet few eosinophils in BAL.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

These data suggest that the presence of the secreted form of RSV G during initial antigen presentation (and not solely the primary or secondary antigenic structure) affects the composition of immune responses to RSV infection. Previous work has shown that immunization with RSV G results in more severe disease and lung pathology following RSV challenge (25, 61). The molecular basis for this alteration in the immune response has not been defined. The unique nature of G provides several attributes which may generate the altered immune response to RSV challenge. First, G is extensively glycosylated: >50% of the weight of the mature protein is contributed by carbohydrate residues, attached predominantly via O-glycosidic bonds (70). Also, G contains a high proportion (30.6%) of serine and threonine residues which serve as acceptors for the O-linked oligosaccharides. Third, G protein lacks homology to any other known paramyxovirus protein. The high proline content of 10.1% has more in common with mucinous glycoproteins than viral glycoproteins (31, 39, 70). G exhibits neither hemagglutinating nor neuraminidase activities (22) and is also unusual in that it lacks both a hydrophobic NH2-terminal signal sequence and a hydrophobic COOH-terminal domain, features present in RSV F and other paramyxovirus proteins (70).

In contrast to previously published studies using recombinant vaccinia virus expressing wild-type RSV G (25, 60, 61), mice primed with recombinant vaccinia virus expressing only membrane-anchored G are partially protected during RSV challenge, with reduced viral titers observed, although illness patterns are similar. However, in the absence of membrane-anchored G, secreted G increases illness and decreases viral clearance. We have shown that priming with secreted G (for both vvWT G and vvM48) is associated with increased IL-5 production and more severe immunopathology, including increased tissue eosinophilia. However, illness correlates with alveolar infiltration of eosinophils, as determined by their presence in BAL, and suggests that secreted G induces factors other than IL-5 which may be responsible for a second step in the activation and migration of eosinophils. These data suggest the secreted form of RSV G modulates the composition of the immune response by inducing IL-5 production and altering patterns of leukocyte trafficking, while the membrane-anchored form of G may have a separate and dominant immunoregulatory effect on factors producing illness.

Several immunoregulatory mechanisms have been described for soluble antigen. Soluble antigen has been shown to regulate the development of germinal center B cells by selectively inducing apoptosis of high-affinity antigen-specific B lymphocytes (50, 56). This ability to direct B-cell differentiation is hypothesized to indicate clonal deletion of self-reactive B cells and, thus, be a mechanism of avoiding autoimmune disease. Soluble antigen will be processed and presented in the context of major histocompatibility (MHC) class II molecules. MHC context of antigen presentation (41), the type of antigen-presenting cell used (11, 54), and the presence of different costimulatory molecules (13, 55) have been shown to regulate the development and maturation of T-cell subsets. Antigen dose may also be a determinant in T-cell differentiation. In most systems, immunization with large doses of antigen induces effector cells exhibiting a type 1 cytokine profile, whereas lower concentrations of priming antigen tend to generate type 2 effector cells (12, 29). However, some antigens have the reversed profile, with high doses favoring development of Th2 cells and low doses inducing Th1 cells (51). Thus, the induction of severe disease by the presence of soluble G during priming suggests that either the concentration or processing of G or its subsequent recognition by selected T-cell subsets may be a key determinant regulating immune responses following subsequent RSV challenge.

Infectious organisms ensure their survival by developing mechanisms to avoid detection or subvert immune responses. Some strategies include production of cytokine receptors by the organism (30) or blocking induction of the immune response at the level of antigen presentation (14, 28). A body of evidence which suggests that induction of Th2-mediated immune responses provides a survival advantage for many intracellular pathogens, including viruses, is also accumulating (13, 21). For example, measles virus suppresses cell-mediated immunity by down-regulation of IL-12 expression through signals mediated by measles virus binding CD46 (33). Also, disease progression and infection with human immunodeficiency virus have been associated with Th2-dominated responses (16, 37). Human immunodeficiency virus infection has been shown to suppress IL-2, IL-12, and IFN-gamma , but not tumor necrosis factor alpha or IL-6, induction by Toxoplasma gondii (15). Thus, the induction of a type 2 T-cell response by secreted RSV G may serve as a defense mechanism the virus has evolved to favorably modulate immune responses.

Previous work has established priming or infection with G-expressing vectors results in increased illness and pathology (61). The ability of RSV G to produce cytokines associated with a Th2 response has been clearly demonstrated (2, 4, 25). In this and other studies, FI-RSV priming has also been shown to induce Th2-type cytokine profiles in mice (19, 62, 69), thereby associating this type of response with the RSV vaccine-enhanced illness seen in children in FI-RSV vaccine studies in the 1960s (32, 34). In this study, we have addressed whether it is the primary or secondary antigen structure of G, or the presence of secreted G or antigens with obligate processing through the endocytic pathway and MHC class II expression, which increases disease severity. The IgG2a isotype antibodies and disease protection observed in mice primed with membrane-anchored G and the IgG1 isotype antibodies and more severe illness induced by immunization with secreted G imply that different Th1- and Th2-associated cytokine profiles may be induced by priming without and with secreted G, respectively. We therefore propose that the link between RSV G immunization, FI-RSV-induced vaccine-enhanced illness, and induction of type 2 cytokine profiles is not induced by G itself but rather results from the initial presentation of G to the immune system in secreted form. This might then promote the induction of Th2 CD4+ T-cell differentiation in part by precluding intracellular antigen processing, presentation of antigen by MHC class I molecules, and loss of the early contribution of CD8+ T cells to the cytokine milieu (17, 59).

Evidence suggests that full activation of eosinophils requires a two-step process involving IL-5, eotaxin, or other cofactors (42, 53). Extracellular matrix proteins (36) and VLA-4 on eosinophils (44) may also be involved in eosinophil recruitment and infiltration. These observations may be invoked to explain the differential patterns of eosinophilia and disease severity induced by priming with membrane-anchored and secreted G. Our data suggest the hypothesis that immunization with any form of G (membrane anchored or secreted) may recruit eosinophils upon challenge via the induction of IL-5, but the presence of secreted G is required for inducing the activation associated with movement of eosinophils into alveolar spaces to produce more severe disease.

The data presented in this paper suggest that priming with secreted RSV G promotes eosinophil recruitment associated with IL-5 production and that illness is associated with the movement of eosinophils from the interstitial compartment in the lung to the alveoli. We propose the secretion of G from RSV-infected cells represents a strategy to modulate and evade effective immune responses. The presence of a small number of alveolar eosinophils in mice primed with membrane-anchored G suggests a direct effect of the primary or secondary antigenic structure of G on the induction of type 2 immune responses that is compounded by its secretion as a soluble protein, resulting in increased eosinophilia. Understanding how secreted G interacts with different elements of the innate and adaptive immune system might provide insight into basic mechanisms of clearance for RSV and other viruses.

    ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grants RO1-AI-37216 (B.S.G.) and RO1-AI-20181 (G.W.W.).

We thank Rauf Kuli-Zade and Peter Veldkamp for technical assistance and James E. Crowe, Jr., for editorial comments.

    FOOTNOTES

* Corresponding author. Mailing address: A-4103 MCN, Vanderbilt University School of Medicine, 1161 21st Ave., Nashville, TN 37232-2582. Phone: (615) 343-3717. Fax: (615) 322-8222. E-mail: Barney.Graham{at}mcmail.vanderbilt.edu.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Alwan, W., W. Kozlowska, and P. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:81-89[Abstract/Free Full Text].
2. Alwan, W., and P. Openshaw. 1993. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. Vaccine 11:431-437[Medline].
3. Alwan, W., F. Record, and P. Openshaw. 1992. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus: comparison with the effects of CD8+ T cells. Clin. Exp. Immunol. 88:527-536[Medline].
4. Alwan, W., F. Record, and P. Openshaw. 1993. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J. Immunol. 150:5211-5218[Abstract].
5. Anderson, L., and C. Heilman. 1995. Protective and disease-enhancing immune response to respiratory syncytial virus. J. Infect. Dis. 171:1-7[Medline].
6. Ball, L., K. Young, K. Anderson, P. Collins, and G. Wertz. 1986. Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc. Natl. Acad. Sci. USA 83:246-250[Abstract/Free Full Text].
7. Bangham, C., M. Cannon, D. Karzon, and B. Askonas. 1985. Cytotoxic T-cell response to respiratory syncytial virus in mice. J. Virol. 56:55-59[Abstract/Free Full Text].
8. Bangham, C., P. Openshaw, A. Ball, A. King, G. Wertz, and B. Askonas. 1986. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J. Immunol. 137:3973-3977[Abstract].
9. Chakrabarti, S., K. Brechling, and B. Moss. 1985. Vaccinia virus expression vector: coexpression of beta -galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403-3409[Abstract/Free Full Text].
10. Connors, M., P. Collins, C. Firestone, A. Sotnikov, A. Waitze, A. Davis, P. Hung, R. Chanock, and B. Murphy. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484[Medline].
11. Conradt, P., and S. Kaufmann. 1995. Impact of antigen-presenting cells on cytokine profiles of human Th clones established after stimulation with Mycobacterium tuberculosis antigens. Infect. Immun. 63:2079-2081[Abstract].
12. Constant, S., C. Pfeiffer, A. Woodard, T. Pasqualini, and K. Bottomly. 1995. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J. Exp. Med. 182:1591-1596[Abstract/Free Full Text].
13. Corry, D., S. Reiner, P. Linsley, and R. Locksley. 1994. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:4142-4148[Abstract].
14. Fruh, K., K. Ahn, H. Djaballah, P. Sempe, P. M. van Endert, R. Tampe, P. A. Peterson, and Y. Yang. 1995. A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415-418[Medline].
15. Gazzinelli, R. T., S. Baia, R. Stevens, M. Baseler, L. Wahl, J. Kovacs, and A. Sher. 1995. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines. J. Immunol. 155:1565-1574[Abstract].
16. Gazzinelli, R. T., M. Makino, S. K. Chattopadhyay, C. M. Snapper, A. Sher, A. W. Hugin, and H. C. Morse. 1992. CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J. Immunol. 148:182-188[Abstract].
17. Graham, B. S. 1996. Immunological determinants of disease caused by respiratory syncytial virus. Trends Microbiol. 4:290-294[Medline].
18. Graham, B. 1995. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am. J. Respir. Crit. Care Med. 152:563-566.
19. Graham, B., G. Henderson, Y. Tang, X. Lu, K. Neuzil, and D. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040[Abstract].
20. Graham, B., M. Perkins, P. Wright, and D. Karzon. 1988. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26:153-162[Medline].
21. Griffin, D. E., and B. J. Ward. 1993. Differential CD4 T cell activation in measles. J. Infect. Dis. 168:275-281[Medline].
22. Gruber, C., and S. Levine. 1983. Respiratory syncytial virus polypeptides. III. The envelope-associated proteins. J. Gen. Virol. 64:825-832[Abstract/Free Full Text].
23. Hall, C., E. Walsh, C. Long, and K. Schnabel. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:693-698[Medline].
24. Hall, W., and S. Martin. 1973. Purification and characterization of measles virus. J. Gen. Virol. 19:175-188[Abstract/Free Full Text].
25. Hancock, G., D. Speelman, K. Heers, E. Bortell, J. Smith, and C. Cosco. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791[Abstract].
26. Hendricks, D., K. Baradaran, K. McIntosh, and J. Patterson. 1987. Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells. J. Gen. Virol. 68:1705-1714[Abstract/Free Full Text].
27. Hendricks, D., K. McIntosh, and J. Patterson. 1988. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J. Virol. 62:2228-2233[Abstract/Free Full Text].
28. Hill, A., P. Jugovic, I. York, G. Russ, J. Bennicnk, J. Yewdell, H. Ploegh, and D. Johnson. 1995. Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-415[Medline].
29. Hosken, N. A., K. Shibuya, A. W. Heath, K. M. Murphy, and A. O'Garra. 1995. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J. Exp. Med. 182:1579-1584[Abstract/Free Full Text].
30. Hu, F. Q., C. A. Smith, and D. J. Pickup. 1994. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 204:343-356[Medline].
31. Johnson, P., M. Spriggs, R. Olmstead, and P. Collins. 1987. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 84:5625-5629[Abstract/Free Full Text].
32. Kapikian, A., R. Mitchell, R. Chanock, R. Shvedoff, and C. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421[Abstract/Free Full Text].
33. Karp, C. L., M. Wysocka, L. M. Wahl, J. M. Ahearn, P. J. Cuomo, B. Sherry, G. Trinchieri, and D. E. Griffin. 1996. Mechanism of suppression of cell-mediated immunity by measles virus. Science 273:228-231[Abstract].
34. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434[Abstract/Free Full Text].
35. Kim, H., S. Leikin, J. Arrobio, C. Brandt, R. Chanock, and R. Parrott. 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 10:75-78[Medline].
36. Kita, H., S. Horie, and G. J. Gleich. 1996. Extracellular matrix proteins attenuate activation and degranulation of stimulated eosinophils. J. Immunol. 156:1174-1181[Abstract].
37. Kurup, V. P., B. W. Seymour, H. Choi, and R. L. Coffman. 1994. Particulate Aspergillus fumigatus antigens elicit a TH2 response in BALB/c mice. J. Allergy Clin. Immunol. 93:1013-1020[Medline].
38. Lambert, D. 1988. Role of oligosaccharides in the structure and function of respiratory syncytial virus glycoproteins. Virology 16:458-466.
39. Langedijk, J., W. Schaaper, R. Meloen, and J. van Oirschot. 1996. Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus. J. Gen. Virol. 77:1249-1257[Abstract/Free Full Text].
40. Levine, S., R. Franco-Klaiber, and P. Paradiso. 1987. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 68:2521-2524[Abstract/Free Full Text].
41. Milich, D., D. Peterson, F. Schodel, J. Jones, and J. Hughes. 1995. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. J. Virol. 69:2776-2785[Abstract].
42. Mould, A. W., K. I. Matthaei, I. G. Young, and P. S. Foster. 1997. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J. Clin. Invest. 99:1064-1071[Medline].
43. Murphy, B., B. Graham, G. Prince, E. Walsh, R. Chanock, D. Karzon, and P. Wright. 1986. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J. Clin. Microbiol. 23:1009-1014[Abstract/Free Full Text].
44. Nakajima, H., H. Sano, T. Nishimura, S. Yoshida, and I. Iwamoto. 1994. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J. Exp. Med. 179:1145-1154[Abstract/Free Full Text].
45. Olmsted, R., N. Elango, G. Prince, B. Murphy, P. Johnson, B. Moss, R. Chanock, and P. Collins. 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. USA 83:7462-7466[Abstract/Free Full Text].
46. Openshaw, P., S. Clarke, and F. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493-500[Abstract/Free Full Text].
47. Palomo, C., B. Garcia-Barreno, C. Penas, and J. Melero. 1991. The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity. J. Gen. Virol. 72:669-675[Abstract/Free Full Text].
48. Pemberton, R., M. Cannon, P. Openshaw, L. Ball, G. Wertz, and B. Askonas. 1987. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J. Gen. Virol. 68:2177-2182[Abstract/Free Full Text].
49. Prince, G., A. Jenson, V. Hemming, B. Murphy, E. Walsh, R. Horswood, and R. Chanock. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57:721-728[Abstract/Free Full Text].
50. Pulendran, B., G. Kannourakis, S. Nouri, K. Smith, and G. Nossal. 1995. Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. Nature 375:331-334[Medline].
51. Rizzo, L. V., R. H. DeKruyff, D. T. Umetsu, and R. R. Caspi. 1995. Regulation of the interaction between Th1 and Th2 T cell clones to provide help for antibody production in vivo. Eur. J. Immunol. 25:708-716[Medline].
52. Roberts, S., D. Lichtenstein, L. Ball, and G. Wertz. 1994. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J. Virol. 68:4538-4546[Abstract/Free Full Text].
53. Rothenberg, M. E., R. Ownbey, P. D. Mehlhop, P. M. Loiselle, M. van de Rijn, J. V. Bonventre, H. C. Oettgen, P. Leder, and A. D. Luster. 1996. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol. Med. 2:334-348[Medline].
54. Schmitz, J., M. Assenmacher, and A. Radbruch. 1993. Regulation of T helper cell cytokine expression: functional dichotomy of antigen-presenting cells. Eur. J. Immunol. 23:191-199[Medline].
55. Shanafelt, M., C. Soderberg, A. Allsup, D. Adelman, G. Peltz, and R. Lahesmaa. 1995. Costimulatory signals can selectively modulate cytokine production by subsets of CD4+ T cells. J. Immunol. 154:1684-1690[Abstract].
56. Shokat, K., and C. Goodnow. 1995. Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature 375:334-338[Medline].
57. Simard, C., F. Nadon, C. Seguin, and M. Trudel. 1995. Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection. Antiviral Res. 28:303-315[Medline].
58. Srikiatkhachorn, A., and T. Braciale. 1997. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71:678-685[Abstract].
59. Stott, E., L. Ball, K. Young, J. Furze, and G. Wertz. 1986. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J. Virol. 60:607-613[Abstract/Free Full Text].
60. Stott, E., G. Taylor, L. Ball, K. Anderson, K. Young, A. King, and G. Wertz. 1987. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:3855-3861[Abstract/Free Full Text].
61. Tang, Y., and B. Graham. 1994. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J. Clin. Invest. 94:1953-1958.
62. Taylor, G., E. Stott, M. Bew, B. Fernie, P. Cote, A. Collins, M. Hughes, and J. Jebbett. 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137-142[Medline].
63. Wagner, D., P. Muelenaer, F. Henderson, M. Snyder, C. Reimer, E. Walsh, L. Anderson, D. Nelson, and B. Murphy. 1989. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections. J. Clin. Microbiol. 27:589-592[Abstract/Free Full Text].
64. Wagner, D., B. Graham, P. Wright, E. Walsh, H. Kim, C. Reimer, D. Nelson, R. Chanock, and B. Murphy. 1986. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J. Clin. Microbiol. 24:304-306[Abstract/Free Full Text].
65. Walsh, E., C. Hall, M. Briselli, M. Brandiss, and J. Schlesinger. 1987. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J. Infect. Dis. 155:1198-1204[Medline].
66. Walsh, E., C. Hall, M. Briselli, M. Brandiss, and J. Schlesinger. 1987. Immunization with glycoprotein subunits of respiratory syncytial virus protect cotton rats against viral infection. J. Infect. Dis. 155:1198-1204.
67. Walsh, E., J. Schlesinger, and M. Brandiss. 1984. Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J. Gen. Virol. 65:761-767[Abstract/Free Full Text].
68. Ward, K., P. Lambden, M. Oglivie, and P. J. Watt. 1983. Antibodies to respiratory syncytial virus polypeptides and their significance in human infection. J. Gen. Virol. 64:1867-1876[Abstract/Free Full Text].
69. Waris, M., C. Tsou, D. Erdman, S. Zaki, and L. Anderson. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:2852-2860[Abstract].
70. Wertz, G., P. Collins, Y. Huang, C. Gruber, and S. Levine. 1985. Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc. Natl. Acad. Sci. USA 82:4075-4079[Abstract/Free Full Text].

J Virol, April 1998, p. 2871-2880, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Percopo, C. M., Qiu, Z., Phipps, S., Foster, P. S., Domachowske, J. B., Rosenberg, H. F. (2009). Pulmonary Eosinophils and Their Role in Immunopathologic Responses to Formalin-Inactivated Pneumonia Virus of Mice. J. Immunol. 183: 604-612 [Abstract] [Full Text]  
  • Olson, M. R., Hartwig, S. M., Varga, S. M. (2008). The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia. J. Immunol. 181: 7958-7968 [Abstract] [Full Text]  
  • Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., Suzuki, H., Karamatsu, K., Yasutomi, Y., Shida, H., Kidokoro, M., Mizuno, K., Matsushima, K., Kohara, M. (2008). Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV. J. Immunol. 181: 6337-6348 [Abstract] [Full Text]  
  • Johnson, T. R., Rothenberg, M. E., Graham, B. S. (2008). Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J. Leukoc. Biol. 84: 748-759 [Abstract] [Full Text]  
  • Ward, T. M., Traina-Dorge, V., Davis, K. A., Gray, W. L. (2008). Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic. J. Gen. Virol. 89: 741-750 [Abstract] [Full Text]  
  • Collins, P. L., Graham, B. S. (2008). Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. J. Virol. 82: 2040-2055 [Full Text]  
  • Yu, J.-R., Kim, S., Lee, J.-B., Chang, J. (2008). Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection. J. Virol. 82: 2350-2357 [Abstract] [Full Text]  
  • Castilow, E. M., Olson, M. R., Meyerholz, D. K., Varga, S. M. (2008). Differential Role of Gamma Interferon in Inhibiting Pulmonary Eosinophilia and Exacerbating Systemic Disease in Fusion Protein-Immunized Mice Undergoing Challenge Infection with Respiratory Syncytial Virus. J. Virol. 82: 2196-2207 [Abstract] [Full Text]  
  • Castilow, E. M., Meyerholz, D. K., Varga, S. M. (2008). IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease. J. Immunol. 180: 2376-2384 [Abstract] [Full Text]  
  • Mok, H., Lee, S., Utley, T. J., Shepherd, B. E., Polosukhin, V. V., Collier, M. L., Davis, N. L., Johnston, R. E., Crowe, J. E. Jr. (2007). Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats. J. Virol. 81: 13710-13722 [Abstract] [Full Text]  
  • Olson, M. R., Varga, S. M. (2007). CD8 T Cells Inhibit Respiratory Syncytial Virus (RSV) Vaccine-Enhanced Disease. J. Immunol. 179: 5415-5424 [Abstract] [Full Text]  
  • Singh, A. M., Moore, P. E., Gern, J. E., Lemanske, R. F. Jr., Hartert, T. V. (2007). Bronchiolitis to Asthma: A Review and Call for Studies of Gene-Virus Interactions in Asthma Causation. Am. J. Respir. Crit. Care Med. 175: 108-119 [Abstract] [Full Text]  
  • Lukacs, N. W., Moore, M. L., Rudd, B. D., Berlin, A. A., Collins, R. D., Olson, S. J., Ho, S. B., Peebles, R. S. Jr (2006). Differential Immune Responses and Pulmonary Pathophysiology Are Induced by Two Different Strains of Respiratory Syncytial Virus. Am. J. Pathol. 169: 977-986 [Abstract] [Full Text]  
  • Milstone, A. P., Brumble, L. M., Barnes, J., Estes, W., Loyd, J. E., Pierson, R. N. III, Dummer, S. (2006). A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 28: 131-137 [Abstract] [Full Text]  
  • Peebles, R. S. Jr., Graham, B. S. (2005). Pathogenesis of Respiratory Syncytial Virus Infection in the Murine Model. Proc Am Thorac Soc 2: 110-115 [Abstract] [Full Text]  
  • Collins, P. L., Murphy, B. R. (2005). New Generation Live Vaccines against Human Respiratory Syncytial Virus Designed by Reverse Genetics. Proc Am Thorac Soc 2: 166-173 [Abstract] [Full Text]  
  • Openshaw, P. J. M., Tregoning, J. S. (2005). Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection. Clin. Microbiol. Rev. 18: 541-555 [Abstract] [Full Text]  
  • McCurdy, L. H., Rutigliano, J. A., Johnson, T. R., Chen, M., Graham, B. S. (2004). Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4. J. Virol. 78: 12471-12479 [Abstract] [Full Text]  
  • Johnson, T. R., Varga, S. M., Braciale, T. J., Graham, B. S. (2004). V{beta}14+ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV. J. Virol. 78: 8753-8760 [Abstract] [Full Text]  
  • Johnson, T. R., Teng, M. N., Collins, P. L., Graham, B. S. (2004). Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV. J. Virol. 78: 6024-6032 [Abstract] [Full Text]  
  • Schwarze, J, Schauer, U (2004). Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein. Thorax 59: 517-521 [Abstract] [Full Text]  
  • Easton, A. J., Domachowske, J. B., Rosenberg, H. F. (2004). Animal Pneumoviruses: Molecular Genetics and Pathogenesis. Clin. Microbiol. Rev. 17: 390-412 [Abstract] [Full Text]  
  • Rutigliano, J. A., Johnson, T. R., Hollinger, T. N., Fischer, J. E., Aung, S., Graham, B. S. (2004). Treatment with Anti-LFA-1 Delays the CD8+ Cytotoxic-T-Lymphocyte Response and Viral Clearance in Mice with Primary Respiratory Syncytial Virus Infection. J. Virol. 78: 3014-3023 [Abstract] [Full Text]  
  • Chang, J., Choi, S. Y., Jin, H. T., Sung, Y. C., Braciale, T. J. (2004). Improved Effector Activity and Memory CD8 T Cell Development by IL-2 Expression during Experimental Respiratory Syncytial Virus Infection. J. Immunol. 172: 503-508 [Abstract] [Full Text]  
  • Haynes, L. M., Jones, L. P., Barskey, A., Anderson, L. J., Tripp, R. A. (2003). Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P. J. Virol. 77: 9831-9844 [Abstract] [Full Text]  
  • Johnson, T. R., Parker, R. A., Johnson, J. E., Graham, B. S. (2003). IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge. J. Immunol. 170: 2037-2045 [Abstract] [Full Text]  
  • Schmidt, U., Beyer, J., Polster, U., Gershwin, L. J., Buchholz, U. J. (2002). Mucosal Immunization with Live Recombinant Bovine Respiratory Syncytial Virus (BRSV) and Recombinant BRSV Lacking the Envelope Glycoprotein G Protects against Challenge with Wild-Type BRSV. J. Virol. 76: 12355-12359 [Abstract] [Full Text]  
  • Lee, C. G., Homer, R. J., Cohn, L., Link, H., Jung, S., Craft, J. E., Graham, B. S., Johnson, T. R., Elias, J. A. (2002). Transgenic Overexpression of Interleukin (IL)-10 in the Lung Causes Mucus Metaplasia, Tissue Inflammation, and Airway Remodeling via IL-13-dependent and -independent Pathways. J. Biol. Chem. 277: 35466-35474 [Abstract] [Full Text]  
  • Johnson, T. R., Hong, S., Van Kaer, L., Koezuka, Y., Graham, B. S. (2002). NK T Cells Contribute to Expansion of CD8+ T Cells and Amplification of Antiviral Immune Responses to Respiratory Syncytial Virus. J. Virol. 76: 4294-4303 [Abstract] [Full Text]  
  • Durbin, J. E., Johnson, T. R., Durbin, R. K., Mertz, S. E., Morotti, R. A., Peebles, R. S., Graham, B. S. (2002). The Role of IFN in Respiratory Syncytial Virus Pathogenesis. J. Immunol. 168: 2944-2952 [Abstract] [Full Text]  
  • Schlender, J., Walliser, G., Fricke, J., Conzelmann, K.-K. (2002). Respiratory Syncytial Virus Fusion Protein Mediates Inhibition of Mitogen-Induced T-Cell Proliferation by Contact. J. Virol. 76: 1163-1170 [Abstract] [Full Text]  
  • Holtzman, M. J., Morton, J. D., Shornick, L. P., Tyner, J. W., O'Sullivan, M. P., Antao, A., Lo, M., Castro, M., Walter, M. J. (2002). Immunity, Inflammation, and Remodeling in the Airway Epithelial Barrier: Epithelial-Viral-Allergic Paradigm. Physiol. Rev. 82: 19-46 [Abstract] [Full Text]  
  • Prince, G. A., Curtis, S. J., Yim, K. C., Porter, D. D. (2001). Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82: 2881-2888 [Abstract] [Full Text]  
  • Haynes, L. M., Moore, D. D., Kurt-Jones, E. A., Finberg, R. W., Anderson, L. J., Tripp, R. A. (2001). Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus. J. Virol. 75: 10730-10737 [Abstract] [Full Text]  
  • Johnson, T. R., Fischer, J. E., Graham, B. S. (2001). Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. J. Gen. Virol. 82: 2107-2116 [Abstract] [Full Text]  
  • Lu, Y. E., Eng, C. H., Shome, S. G., Kielian, M. (2001). In Vivo Generation and Characterization of a Soluble Form of the Semliki Forest Virus Fusion Protein. J. Virol. 75: 8329-8339 [Abstract] [Full Text]  
  • Simmons, C. P., Hussell, T., Sparer, T., Walzl, G., Openshaw, P., Dougan, G. (2001). Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses. J. Immunol. 166: 1106-1113 [Abstract] [Full Text]  
  • Yamamoto, N., Suzuki, S., Suzuki, Y., Shirai, A., Nakazawa, M., Suzuki, M., Takamasu, T., Nagashima, Y., Minami, M., Ishigatsubo, Y. (2001). Immune Response Induced by Airway Sensitization after Influenza A Virus Infection Depends on Timing of Antigen Exposure in Mice. J. Virol. 75: 499-505 [Abstract] [Full Text]  
  • Barr, F. E., Pedigo, H., Johnson, T. R., Shepherd, V. L. (2000). Surfactant Protein-A Enhances Uptake of Respiratory Syncytial Virus by Monocytes and U937 Macrophages. Am. J. Respir. Cell Mol. Bio. 23: 586-592 [Abstract] [Full Text]  
  • Smith, P. M., Zhang, Y., Grafton, W. D., Jennings, S. R., O'Callaghan, D. J. (2000). Severe Murine Lung Immunopathology Elicited by the Pathogenic Equine Herpesvirus 1 Strain RacL11 Correlates with Early Production of Macrophage Inflammatory Proteins 1alpha , 1beta , and 2 and Tumor Necrosis Factor Alpha. J. Virol. 74: 10034-10040 [Abstract] [Full Text]  
  • Tripp, R. A., Jones, L., Anderson, L. J. (2000). Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse. J. Virol. 74: 6227-6229 [Abstract] [Full Text]  
  • Tripp, R. A., Moore, D., Winter, J., Anderson, L. J. (2000). Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice. J. Virol. 74: 1614-1622 [Abstract] [Full Text]  
  • Sullender, W. M. (2000). Respiratory Syncytial Virus Genetic and Antigenic Diversity. Clin. Microbiol. Rev. 13: 1-15 [Abstract] [Full Text]  
  • Bembridge, G. P., Lopez, J. A., Bustos, R., Melero, J. A., Cook, R., Mason, H., Taylor, G. (1999). Priming with a Secreted Form of the Fusion Protein of Respiratory Syncytial Virus (RSV) Promotes Interleukin-4 (IL-4) and IL-5 Production but Not Pulmonary Eosinophilia following RSV Challenge. J. Virol. 73: 10086-10094 [Abstract] [Full Text]  
  • Johnson, T. R., Graham, B. S. (1999). Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism. J. Virol. 73: 8485-8495 [Abstract] [Full Text]  
  • Tripp, R. A., Moore, D., Jones, L., Sullender, W., Winter, J., Anderson, L. J. (1999). Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice. J. Virol. 73: 7099-7107 [Abstract] [Full Text]  
  • Srikiatkhachorn, A., Chang, W., Braciale, T. J. (1999). Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent. J. Virol. 73: 6590-6597 [Abstract] [Full Text]  
  • Feldman, S. A., Hendry, R. M., Beeler, J. A. (1999). Identification of a Linear Heparin Binding Domain for Human Respiratory Syncytial Virus Attachment Glycoprotein G. J. Virol. 73: 6610-6617 [Abstract] [Full Text]  
  • Fearon, D.T. (1999). Innate immunity and the biological relevance of the acquired immune response. QJM 92: 235-237 [Full Text]  
  • Hussell, T., Georgiou, A., Sparer, T. E., Matthews, S., Pala, P., Openshaw, P. J. M. (1998). Host Genetic Determinants of Vaccine-Induced Eosinophilia During Respiratory Syncytial Virus Infection. J. Immunol. 161: 6215-6222 [Abstract] [Full Text]  
  • Tebbey, P. W., Hagen, M., Hancock, G. E. (1998). Atypical Pulmonary Eosinophilia Is Mediated by a Specific Amino Acid Sequence of the Attachment (G) Protein of Respiratory Syncytial Virus. JEM 188: 1967-1972 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»